{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.057","statisticalComment":"Reported p-values are unadjusted and 1-sided","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45","upperLimit":"58","value":"52"},{"groupId":"OG001","lowerLimit":"38","upperLimit":"51","value":"44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"218"}],"units":"Participants"}],"description":"Comparing regimens that contain bevacizumab (arms 2\\&4) versus not (arms 1\\&3).","dispersionType":"95% Confidence Interval","groups":[{"description":"Factor B is the addition or not of bevacizumab: the experimental regimens included bevacizumab (Arms 2 \\& 4).","id":"OG000","title":"Factor B: Bevacizumab"},{"description":"Factor B is the addition or not of bevacizumab: the control regimens did not include bevacizumab (Arms 1 \\& 3)","id":"OG001","title":"Factor B: No Bevacizumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At the time of definitive surgical removal, up to 28 weeks","title":"Pathologic Complete Response (pCR) in the Breast and Axilla. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is) Plus the Absence of Any Tumor Deposit >0.2 mm in Sampled Axillary Nodes (ypT0/isN0).","type":"SECONDARY","unitOfMeasure":"percentage of participants with pCR"}